Pretreatment characteristics of the 47 patients treated with lenalidomide
| Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 69 (36-84) |
| Sex, female/male | 23/24 |
| Diagnosis according to WHO | |
| Pure RA | 2 (4%) |
| RCMD-RS | 1 (2%) |
| RAEB-1 | 6 (13%) |
| RAEB-2 | 20 (43%) |
| AML (RAEB-T according to FAB classification) | 18 (38%) |
| IPSS score | |
| Int-2 | 28 (60%) |
| High | 19 (40%) |
| Cytogenetics | |
| Isolated del 5q | 9 (19%) |
| del 5q and 1 additional abnormality | 11 (23%) |
| del 5q with 2 or more additional abnormalities | 27 (58%) |
| RBC transfusion requirement | 43/47 (91%) |
| ANC < 1000/mm3 | 18/47 (38%) |
| Platelets < 100 000/mm3 | 27/47 (57%) |
| Bone marrow blasts > 10% | 37/47 (78%) |
| Characteristic . | Value . |
|---|---|
| Age, y, median (range) | 69 (36-84) |
| Sex, female/male | 23/24 |
| Diagnosis according to WHO | |
| Pure RA | 2 (4%) |
| RCMD-RS | 1 (2%) |
| RAEB-1 | 6 (13%) |
| RAEB-2 | 20 (43%) |
| AML (RAEB-T according to FAB classification) | 18 (38%) |
| IPSS score | |
| Int-2 | 28 (60%) |
| High | 19 (40%) |
| Cytogenetics | |
| Isolated del 5q | 9 (19%) |
| del 5q and 1 additional abnormality | 11 (23%) |
| del 5q with 2 or more additional abnormalities | 27 (58%) |
| RBC transfusion requirement | 43/47 (91%) |
| ANC < 1000/mm3 | 18/47 (38%) |
| Platelets < 100 000/mm3 | 27/47 (57%) |
| Bone marrow blasts > 10% | 37/47 (78%) |